Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Amneal Pharmaceuticals, LLC

US Class III Ongoing · initiated 2026-06-03

Cross Contamination with Other Products: due to a potential for cross-contamination with Acemetacin API due to an issue at the API manufacturer.

ChloraPrep 1 mL and 1.5 mL Applicator - Clear

Canada Type II Ongoing · initiated 2026-06-03

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited

US Class II Ongoing · initiated 2026-06-02

CGMP Deviations; deficiencies observed during FDA inspection

Central Admixture Pharmacy Services, Inc.

US Class II Ongoing · initiated 2026-06-02

Incorrect product formulation: bag did not contain copper and famotidine per label.

ANI Pharmaceuticals, Inc.

US Class III Ongoing · initiated 2026-06-02

Presence of foreign substance

Ascend Laboratories, LLC

US Class II Ongoing · initiated 2026-06-01

Failed Dissolution Specifications: An out-of-specification (OOS) result was observed during the 9th month of dissolution test analysis

BEEKEEPER'S NATURALS USA INC.

US Class I Ongoing · initiated 2026-06-01

Microbial Contamination of Non-Sterile Products

Sandoz Inc

US Class III Ongoing · initiated 2026-06-01

Labeling: Incorrect or Missing Lot and/or Exp Date

SUN PHARMACEUTICAL INDUSTRIES INC

US Class III Ongoing · initiated 2026-06-01

Failed Impurities/Degradation Specifications

SUN PHARMACEUTICAL INDUSTRIES INC

US Class II Ongoing · initiated 2026-05-29

Presence of Foreign Substance:This recall has been initiated in response to a product quality complaint reported for black/brown specs and particles within the …

Golden State Medical Supply Inc.

US Class II Ongoing · initiated 2026-05-29

Failed Dissolution Specifications: During 12-month long-term stability testing, subject lot was out of specification (low) for stage 3 dissolution at the 24-hou…

Gasco Industrial Corp.

US Class II Ongoing · initiated 2026-05-29

Subpotent drug